Accelerating the drug delivery pipeline for acute and chronic pancreatitis-knowledge gaps and research opportunities: Overview summary of a National Institute of Diabetes and Digestive and Kidney Diseases workshop

Aliye Uc, Dana Andersen, Drucy Borowitz, Marshall J. Glesby, Julia Mayerle, Robert Sutton, Stephen J. Pandol

Research output: Contribution to journalArticle

Abstract

A workshop was sponsored by the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, on July 25, 2018, in Pittsburgh, Penn. The workshop was designed to bring together a multidisciplinary group of experts to accelerate the development of therapeutics for clinical application in inflammatory diseases of the exocrine pancreas. Three separate working groups (acute pancreatitis, recurrent acute pancreatitis, and chronic pancreatitis) were formed to address the needs, gaps, and opportunities. The working groups included patients with pancreatic diseases, pharmaceutical company leaders, basic scientists, clinical researchers, and representatives from the US Food and Drug Administration to assist with regulatory considerations and to identify the unmet needs, research targets, and opportunities to provide direction for successful development of therapeutic agents in these diseases. This article represents the summary of the overview presentations at the National Institute of Diabetes and Digestive and Kidney Diseases workshop including an ongoing drug trial in acute pancreatitis; a successful drug development network developed by the Cystic Fibrosis Foundation; and considerations for subject selection in drug trials, incorporating Food and Drug Administration guidelines on clinical trial design and clinical outcome measures. The summaries of each working group follow separately in accompanying articles.

LanguageEnglish (US)
Pages1180-1184
Number of pages5
JournalPancreas
Volume47
Issue number10
DOIs
StatePublished - Nov 1 2018

Fingerprint

National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
Chronic Pancreatitis
Pancreatitis
Education
United States Food and Drug Administration
Research
Pharmaceutical Preparations
Exocrine Pancreas
Pancreatic Diseases
National Institutes of Health (U.S.)
Cystic Fibrosis
Patient Selection
Research Personnel
Outcome Assessment (Health Care)
Clinical Trials
Guidelines
Therapeutics

Keywords

  • clinic trial
  • drug development
  • pancreatitis
  • patient-reported outcomes
  • study design

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Accelerating the drug delivery pipeline for acute and chronic pancreatitis-knowledge gaps and research opportunities : Overview summary of a National Institute of Diabetes and Digestive and Kidney Diseases workshop. / Uc, Aliye; Andersen, Dana; Borowitz, Drucy; Glesby, Marshall J.; Mayerle, Julia; Sutton, Robert; Pandol, Stephen J.

In: Pancreas, Vol. 47, No. 10, 01.11.2018, p. 1180-1184.

Research output: Contribution to journalArticle

@article{9e168f9aff5b456ab1f03eb193b8273b,
title = "Accelerating the drug delivery pipeline for acute and chronic pancreatitis-knowledge gaps and research opportunities: Overview summary of a National Institute of Diabetes and Digestive and Kidney Diseases workshop",
abstract = "A workshop was sponsored by the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, on July 25, 2018, in Pittsburgh, Penn. The workshop was designed to bring together a multidisciplinary group of experts to accelerate the development of therapeutics for clinical application in inflammatory diseases of the exocrine pancreas. Three separate working groups (acute pancreatitis, recurrent acute pancreatitis, and chronic pancreatitis) were formed to address the needs, gaps, and opportunities. The working groups included patients with pancreatic diseases, pharmaceutical company leaders, basic scientists, clinical researchers, and representatives from the US Food and Drug Administration to assist with regulatory considerations and to identify the unmet needs, research targets, and opportunities to provide direction for successful development of therapeutic agents in these diseases. This article represents the summary of the overview presentations at the National Institute of Diabetes and Digestive and Kidney Diseases workshop including an ongoing drug trial in acute pancreatitis; a successful drug development network developed by the Cystic Fibrosis Foundation; and considerations for subject selection in drug trials, incorporating Food and Drug Administration guidelines on clinical trial design and clinical outcome measures. The summaries of each working group follow separately in accompanying articles.",
keywords = "clinic trial, drug development, pancreatitis, patient-reported outcomes, study design",
author = "Aliye Uc and Dana Andersen and Drucy Borowitz and Glesby, {Marshall J.} and Julia Mayerle and Robert Sutton and Pandol, {Stephen J.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1097/MPA.0000000000001176",
language = "English (US)",
volume = "47",
pages = "1180--1184",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Accelerating the drug delivery pipeline for acute and chronic pancreatitis-knowledge gaps and research opportunities

T2 - Pancreas

AU - Uc, Aliye

AU - Andersen, Dana

AU - Borowitz, Drucy

AU - Glesby, Marshall J.

AU - Mayerle, Julia

AU - Sutton, Robert

AU - Pandol, Stephen J.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - A workshop was sponsored by the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, on July 25, 2018, in Pittsburgh, Penn. The workshop was designed to bring together a multidisciplinary group of experts to accelerate the development of therapeutics for clinical application in inflammatory diseases of the exocrine pancreas. Three separate working groups (acute pancreatitis, recurrent acute pancreatitis, and chronic pancreatitis) were formed to address the needs, gaps, and opportunities. The working groups included patients with pancreatic diseases, pharmaceutical company leaders, basic scientists, clinical researchers, and representatives from the US Food and Drug Administration to assist with regulatory considerations and to identify the unmet needs, research targets, and opportunities to provide direction for successful development of therapeutic agents in these diseases. This article represents the summary of the overview presentations at the National Institute of Diabetes and Digestive and Kidney Diseases workshop including an ongoing drug trial in acute pancreatitis; a successful drug development network developed by the Cystic Fibrosis Foundation; and considerations for subject selection in drug trials, incorporating Food and Drug Administration guidelines on clinical trial design and clinical outcome measures. The summaries of each working group follow separately in accompanying articles.

AB - A workshop was sponsored by the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, on July 25, 2018, in Pittsburgh, Penn. The workshop was designed to bring together a multidisciplinary group of experts to accelerate the development of therapeutics for clinical application in inflammatory diseases of the exocrine pancreas. Three separate working groups (acute pancreatitis, recurrent acute pancreatitis, and chronic pancreatitis) were formed to address the needs, gaps, and opportunities. The working groups included patients with pancreatic diseases, pharmaceutical company leaders, basic scientists, clinical researchers, and representatives from the US Food and Drug Administration to assist with regulatory considerations and to identify the unmet needs, research targets, and opportunities to provide direction for successful development of therapeutic agents in these diseases. This article represents the summary of the overview presentations at the National Institute of Diabetes and Digestive and Kidney Diseases workshop including an ongoing drug trial in acute pancreatitis; a successful drug development network developed by the Cystic Fibrosis Foundation; and considerations for subject selection in drug trials, incorporating Food and Drug Administration guidelines on clinical trial design and clinical outcome measures. The summaries of each working group follow separately in accompanying articles.

KW - clinic trial

KW - drug development

KW - pancreatitis

KW - patient-reported outcomes

KW - study design

UR - http://www.scopus.com/inward/record.url?scp=85055076854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055076854&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000001176

DO - 10.1097/MPA.0000000000001176

M3 - Article

VL - 47

SP - 1180

EP - 1184

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 10

ER -